

NEWS RELEASE



NIPPON SHINYAKU CO., LTD.

October 2, 2025

**Brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne Muscular
Dystrophy: Presenting 3.5-Year Clinical Trial Data at the World Muscle Society
2025 Congress**

Kyoto, Japan, October 2, 2025 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters, Kyoto; President, Toru Nakai) announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City, Tokyo; President, Kazuyuki Nakagome) will present 3.5-year efficacy and safety data from the open-label extension of an investigator-initiated clinical trial of brogidirsen (NS-089/NCNP-02) for the treatment of Duchenne muscular dystrophy at the 30th annual International Congress of the World Muscle Society, to be held from October 7th to 11th, 2025.

To access to the poster presentation during the conference period, you will need to register on the website of the Congress. For details, please visit <https://www.wms2025.com/>.

Brogidirsen is an antisense oligonucleotide co-discovered by Nippon Shinyaku and NCNP, and is expected to be a therapeutic drug for Duchenne muscular dystrophy patients who have dystrophin gene mutations that are amenable to exon 44 skipping. A global Phase II study of brogidirsen is being conducted by Nippon Shinyaku and its subsidiary NS Pharma, Inc. (Headquarters: New Jersey, USA; President: Yukiteru Sugiyama).

Nippon Shinyaku has been working actively with a sense of mission to develop agents for the treatment of intractable and rare diseases, with a view to launching products for DMD patients as soon as possible.

Contact

Corporate Communications Dept., Nippon Shinyaku
e_mail_kouhou@po.nippon-shinyaku.co.jp